Adline Chem Lab Ltd.
Adline Chem Lab Ltd. (ADLINE.BO) Stock Competitors & Peer Comparison
See (ADLINE.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADLINE.BO | ₹12.50 | -1.26% | 73.1M | N/A | N/A | N/A |
| MEDPLUS.NS | ₹827.75 | -0.78% | 99.3B | 47.93 | ₹17.27 | N/A |
| MEDPLUS.BO | ₹827.20 | -0.83% | 99.3B | 47.90 | ₹17.27 | N/A |
| GUJTHEM.BO | ₹251.55 | -6.37% | 27.4B | 57.43 | ₹4.38 | +0.27% |
| KPL.BO | ₹1,391.10 | -4.50% | 14.4B | 25.53 | ₹54.48 | N/A |
| SHUKRAPHAR.BO | ₹31.93 | -3.42% | 14B | -159.65 | -₹0.20 | +0.06% |
| FREDUN.BO | ₹1,693.75 | -1.27% | 9.1B | 24.20 | ₹69.99 | +0.04% |
| SASTASUNDR.NS | ₹274.85 | -0.97% | 8.7B | 33.56 | ₹8.19 | N/A |
| SASTASUNDR.BO | ₹274.15 | -0.51% | 8.7B | 33.51 | ₹8.18 | N/A |
| ANUHPHR.BO | ₹70.21 | -1.68% | 7B | 16.80 | ₹4.18 | +2.14% |
Stock Comparison
ADLINE.BO vs MEDPLUS.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, MEDPLUS.NS has a market cap of 99.3B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while MEDPLUS.NS trades at ₹827.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas MEDPLUS.NS's P/E ratio is 47.93. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDPLUS.NS's competition here
ADLINE.BO vs MEDPLUS.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, MEDPLUS.BO has a market cap of 99.3B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while MEDPLUS.BO trades at ₹827.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas MEDPLUS.BO's P/E ratio is 47.90. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDPLUS.BO's competition here
ADLINE.BO vs GUJTHEM.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, GUJTHEM.BO has a market cap of 27.4B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while GUJTHEM.BO trades at ₹251.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas GUJTHEM.BO's P/E ratio is 57.43. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, ADLINE.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GUJTHEM.BO's competition here
ADLINE.BO vs KPL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, KPL.BO has a market cap of 14.4B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while KPL.BO trades at ₹1,391.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas KPL.BO's P/E ratio is 25.53. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, ADLINE.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KPL.BO's competition here
ADLINE.BO vs SHUKRAPHAR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SHUKRAPHAR.BO has a market cap of 14B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SHUKRAPHAR.BO trades at ₹31.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SHUKRAPHAR.BO's P/E ratio is -159.65. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, ADLINE.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SHUKRAPHAR.BO's competition here
ADLINE.BO vs FREDUN.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, FREDUN.BO has a market cap of 9.1B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while FREDUN.BO trades at ₹1,693.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas FREDUN.BO's P/E ratio is 24.20. In terms of profitability, ADLINE.BO's ROE is N/A, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, ADLINE.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check FREDUN.BO's competition here
ADLINE.BO vs SASTASUNDR.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SASTASUNDR.NS has a market cap of 8.7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SASTASUNDR.NS trades at ₹274.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SASTASUNDR.NS's P/E ratio is 33.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, ADLINE.BO is more volatile compared to SASTASUNDR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check SASTASUNDR.NS's competition here
ADLINE.BO vs SASTASUNDR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SASTASUNDR.BO has a market cap of 8.7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SASTASUNDR.BO trades at ₹274.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SASTASUNDR.BO's P/E ratio is 33.51. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, ADLINE.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check SASTASUNDR.BO's competition here
ADLINE.BO vs ANUHPHR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ANUHPHR.BO has a market cap of 7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ANUHPHR.BO trades at ₹70.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ANUHPHR.BO's P/E ratio is 16.80. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, ADLINE.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check ANUHPHR.BO's competition here
ADLINE.BO vs BPLPHARMA.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, BPLPHARMA.BO has a market cap of 6.5B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while BPLPHARMA.BO trades at ₹939.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas BPLPHARMA.BO's P/E ratio is -21.98. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BPLPHARMA.BO's competition here
ADLINE.BO vs ALBERTDA.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ALBERTDA.BO's competition here
ADLINE.BO vs SUDARSHAN.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SUDARSHAN.BO has a market cap of 5.8B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SUDARSHAN.BO trades at ₹24.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SUDARSHAN.BO's P/E ratio is 28.88. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, ADLINE.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SUDARSHAN.BO's competition here
ADLINE.BO vs SGRL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SGRL.BO has a market cap of 5.7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SGRL.BO trades at ₹441.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SGRL.BO's P/E ratio is 31.36. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, ADLINE.BO is less volatile compared to SGRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SGRL.BO's competition here
ADLINE.BO vs PRAVEG.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PRAVEG.BO has a market cap of 5.2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PRAVEG.BO trades at ₹199.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PRAVEG.BO's P/E ratio is -136.34. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PRAVEG.BO's competition here
ADLINE.BO vs JENBURPH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, JENBURPH.BO has a market cap of 4.5B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while JENBURPH.BO trades at ₹1,010.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas JENBURPH.BO's P/E ratio is 13.76. In terms of profitability, ADLINE.BO's ROE is N/A, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, ADLINE.BO is less volatile compared to JENBURPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check JENBURPH.BO's competition here
ADLINE.BO vs VIKRAMTH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, VIKRAMTH.BO has a market cap of 4.4B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while VIKRAMTH.BO trades at ₹140.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas VIKRAMTH.BO's P/E ratio is 12.92. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, ADLINE.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VIKRAMTH.BO's competition here
ADLINE.BO vs INFINIUM.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, INFINIUM.NS has a market cap of 3.1B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while INFINIUM.NS trades at ₹199.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas INFINIUM.NS's P/E ratio is 33.06. In terms of profitability, ADLINE.BO's ROE is N/A, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to INFINIUM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check INFINIUM.NS's competition here
ADLINE.BO vs TLL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TLL.BO has a market cap of 3.1B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TLL.BO trades at ₹258.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TLL.BO's P/E ratio is 20.80. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, ADLINE.BO is less volatile compared to TLL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TLL.BO's competition here
ADLINE.BO vs ZENOTECH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ZENOTECH.BO has a market cap of 2.2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ZENOTECH.BO trades at ₹35.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ZENOTECH.BO's P/E ratio is 64.35. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENOTECH.BO's competition here
ADLINE.BO vs BDH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, BDH.BO has a market cap of 2.1B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while BDH.BO trades at ₹358.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas BDH.BO's P/E ratio is 19.78. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, ADLINE.BO is less volatile compared to BDH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BDH.BO's competition here
ADLINE.BO vs KERALAYUR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, KERALAYUR.BO has a market cap of 2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while KERALAYUR.BO trades at ₹164.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas KERALAYUR.BO's P/E ratio is -8.41. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, ADLINE.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KERALAYUR.BO's competition here
ADLINE.BO vs TRANSCHEM.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TRANSCHEM.BO has a market cap of 2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TRANSCHEM.BO trades at ₹161.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TRANSCHEM.BO's P/E ratio is 67.08. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to TRANSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TRANSCHEM.BO's competition here
ADLINE.BO vs GENNEX.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, GENNEX.BO has a market cap of 1.9B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while GENNEX.BO trades at ₹8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas GENNEX.BO's P/E ratio is 10.82. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, ADLINE.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GENNEX.BO's competition here
ADLINE.BO vs AMBALALSA.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, AMBALALSA.BO has a market cap of 1.9B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while AMBALALSA.BO trades at ₹25.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas AMBALALSA.BO's P/E ratio is 18.47. In terms of profitability, ADLINE.BO's ROE is N/A, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to AMBALALSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check AMBALALSA.BO's competition here
ADLINE.BO vs SYSCHEM.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SYSCHEM.BO has a market cap of 1.9B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SYSCHEM.BO trades at ₹43.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SYSCHEM.BO's P/E ratio is 29.09. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SYSCHEM.BO's competition here
ADLINE.BO vs QUESTLAB.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, QUESTLAB.NS has a market cap of 1.8B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while QUESTLAB.NS trades at ₹108.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas QUESTLAB.NS's P/E ratio is 13.09. In terms of profitability, ADLINE.BO's ROE is N/A, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to QUESTLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check QUESTLAB.NS's competition here
ADLINE.BO vs OXYGENTAPH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, OXYGENTAPH.BO has a market cap of 1.7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while OXYGENTAPH.BO trades at ₹46.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas OXYGENTAPH.BO's P/E ratio is -9.89. In terms of profitability, ADLINE.BO's ROE is N/A, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, ADLINE.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check OXYGENTAPH.BO's competition here
ADLINE.BO vs SANJIVIN.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SANJIVIN.BO has a market cap of 1.7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SANJIVIN.BO trades at ₹139.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SANJIVIN.BO's P/E ratio is 21.21. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, ADLINE.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SANJIVIN.BO's competition here
ADLINE.BO vs AUROLAB.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, AUROLAB.BO has a market cap of 1.7B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while AUROLAB.BO trades at ₹272.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas AUROLAB.BO's P/E ratio is 52.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, ADLINE.BO is less volatile compared to AUROLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check AUROLAB.BO's competition here
ADLINE.BO vs PARNAXLAB.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PARNAXLAB.BO trades at ₹133.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PARNAXLAB.BO's P/E ratio is 12.20. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, ADLINE.BO is more volatile compared to PARNAXLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check PARNAXLAB.BO's competition here
ADLINE.BO vs NATCAPSUQ.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, NATCAPSUQ.BO has a market cap of 1.4B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while NATCAPSUQ.BO trades at ₹139.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas NATCAPSUQ.BO's P/E ratio is -7.51. In terms of profitability, ADLINE.BO's ROE is N/A, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to NATCAPSUQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check NATCAPSUQ.BO's competition here
ADLINE.BO vs PANCHSHEEL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PANCHSHEEL.BO has a market cap of 1.3B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PANCHSHEEL.BO trades at ₹100.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PANCHSHEEL.BO's P/E ratio is 11.01. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, ADLINE.BO is less volatile compared to PANCHSHEEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PANCHSHEEL.BO's competition here
ADLINE.BO vs CORALAB.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, CORALAB.BO has a market cap of 1.3B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while CORALAB.BO trades at ₹362.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas CORALAB.BO's P/E ratio is 9.25. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, ADLINE.BO is less volatile compared to CORALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CORALAB.BO's competition here
ADLINE.BO vs SOTAC.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SOTAC.NS has a market cap of 1.3B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SOTAC.NS trades at ₹115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SOTAC.NS's P/E ratio is 14.86. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is more volatile compared to SOTAC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check SOTAC.NS's competition here
ADLINE.BO vs SMRUTHIORG.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SMRUTHIORG.BO has a market cap of 1.2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SMRUTHIORG.BO trades at ₹106.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SMRUTHIORG.BO's P/E ratio is 26.59. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, ADLINE.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SMRUTHIORG.BO's competition here
ADLINE.BO vs KIMIABL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, KIMIABL.BO has a market cap of 1.2B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while KIMIABL.BO trades at ₹25.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KIMIABL.BO's competition here
ADLINE.BO vs TYCHE.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TYCHE.BO trades at ₹104.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TYCHE.BO's P/E ratio is 15.67. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to TYCHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TYCHE.BO's competition here
ADLINE.BO vs PHARMAID.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PHARMAID.BO trades at ₹30.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PHARMAID.BO's P/E ratio is -5.91. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, ADLINE.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PHARMAID.BO's competition here
ADLINE.BO vs LACTOSE.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, LACTOSE.BO has a market cap of 984.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while LACTOSE.BO trades at ₹78.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas LACTOSE.BO's P/E ratio is 20.26. In terms of profitability, ADLINE.BO's ROE is N/A, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to LACTOSE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check LACTOSE.BO's competition here
ADLINE.BO vs MERCURYLAB.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, MERCURYLAB.BO has a market cap of 876M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while MERCURYLAB.BO trades at ₹730.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas MERCURYLAB.BO's P/E ratio is 18.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, ADLINE.BO is less volatile compared to MERCURYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MERCURYLAB.BO's competition here
ADLINE.BO vs MAKERSL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, MAKERSL.BO has a market cap of 858.8M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while MAKERSL.BO trades at ₹145.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas MAKERSL.BO's P/E ratio is 70.31. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MAKERSL.BO's competition here
ADLINE.BO vs DENISCHEM.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, DENISCHEM.BO has a market cap of 835.5M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while DENISCHEM.BO trades at ₹60.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas DENISCHEM.BO's P/E ratio is 9.59. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check DENISCHEM.BO's competition here
ADLINE.BO vs SOURCENTRL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SOURCENTRL.BO has a market cap of 715.1M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SOURCENTRL.BO trades at ₹111.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SOURCENTRL.BO's P/E ratio is 25.66. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SOURCENTRL.BO's competition here
ADLINE.BO vs CONCORD.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, CONCORD.BO has a market cap of 699.6M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while CONCORD.BO trades at ₹70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas CONCORD.BO's P/E ratio is 159.80. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CONCORD.BO's competition here
ADLINE.BO vs BIBCL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, BIBCL.BO has a market cap of 674.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while BIBCL.BO trades at ₹15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas BIBCL.BO's P/E ratio is -4.71. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ADLINE.BO is less volatile compared to BIBCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BIBCL.BO's competition here
ADLINE.BO vs BACPHAR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, BACPHAR.BO has a market cap of 661M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while BACPHAR.BO trades at ₹46.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas BACPHAR.BO's P/E ratio is 92.10. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BACPHAR.BO's competition here
ADLINE.BO vs ZENITHDRUG.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ZENITHDRUG.NS has a market cap of 653.4M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ZENITHDRUG.NS trades at ₹38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ZENITHDRUG.NS's P/E ratio is 9.11. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENITHDRUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENITHDRUG.NS's competition here
ADLINE.BO vs GODAVARI.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, GODAVARI.BO has a market cap of 645.2M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while GODAVARI.BO trades at ₹85.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas GODAVARI.BO's P/E ratio is -94.15. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GODAVARI.BO's competition here
ADLINE.BO vs SUNLOC.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SUNLOC.BO has a market cap of 641.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SUNLOC.BO trades at ₹62.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SUNLOC.BO's P/E ratio is 22.44. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is more volatile compared to SUNLOC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check SUNLOC.BO's competition here
ADLINE.BO vs VILINBIO.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, VILINBIO.NS has a market cap of 521M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while VILINBIO.NS trades at ₹37.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas VILINBIO.NS's P/E ratio is 233.44. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is more volatile compared to VILINBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check VILINBIO.NS's competition here
ADLINE.BO vs PHRMASI.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PHRMASI.BO has a market cap of 510.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PHRMASI.BO trades at ₹74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PHRMASI.BO's P/E ratio is 2.88. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, ADLINE.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check PHRMASI.BO's competition here
ADLINE.BO vs VISTAPH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, VISTAPH.BO has a market cap of 448.7M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while VISTAPH.BO trades at ₹7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas VISTAPH.BO's P/E ratio is -5.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, ADLINE.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VISTAPH.BO's competition here
ADLINE.BO vs VEERHEALTH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, VEERHEALTH.BO has a market cap of 400.8M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while VEERHEALTH.BO trades at ₹20.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas VEERHEALTH.BO's P/E ratio is 50.10. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is more volatile compared to VEERHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check VEERHEALTH.BO's competition here
ADLINE.BO vs PANJON.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PANJON.BO has a market cap of 394.8M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PANJON.BO trades at ₹23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PANJON.BO's P/E ratio is 92.00. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PANJON.BO's competition here
ADLINE.BO vs VRL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, VRL.BO has a market cap of 342.1M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while VRL.BO trades at ₹107.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas VRL.BO's P/E ratio is 9.15. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, ADLINE.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check VRL.BO's competition here
ADLINE.BO vs SHELTER.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SHELTER.BO has a market cap of 335.4M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SHELTER.BO trades at ₹29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SHELTER.BO's P/E ratio is 5.36. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, ADLINE.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SHELTER.BO's competition here
ADLINE.BO vs SANDUPHQ.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SANDUPHQ.BO has a market cap of 322.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SANDUPHQ.BO trades at ₹33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SANDUPHQ.BO's P/E ratio is 15.81. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to SANDUPHQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SANDUPHQ.BO's competition here
ADLINE.BO vs ROOPAIND.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ROOPAIND.BO has a market cap of 316.4M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ROOPAIND.BO trades at ₹40.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ROOPAIND.BO's P/E ratio is 16.35. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, ADLINE.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ROOPAIND.BO's competition here
ADLINE.BO vs MEDICAPQ.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, MEDICAPQ.BO has a market cap of 301.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while MEDICAPQ.BO trades at ₹24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas MEDICAPQ.BO's P/E ratio is -6.90. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDICAPQ.BO's competition here
ADLINE.BO vs MEDIORG.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, MEDIORG.NS has a market cap of 295.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while MEDIORG.NS trades at ₹21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas MEDIORG.NS's P/E ratio is 5.79. In terms of profitability, ADLINE.BO's ROE is N/A, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to MEDIORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check MEDIORG.NS's competition here
ADLINE.BO vs TRIMURTHI.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check TRIMURTHI.BO's competition here
ADLINE.BO vs GUJTERC.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, GUJTERC.BO has a market cap of 257.6M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while GUJTERC.BO trades at ₹33.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas GUJTERC.BO's P/E ratio is -17.68. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, ADLINE.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check GUJTERC.BO's competition here
ADLINE.BO vs ANG.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ANG.BO has a market cap of 252.2M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ANG.BO trades at ₹19.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ANG.BO's P/E ratio is -2.14. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, ADLINE.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ANG.BO's competition here
ADLINE.BO vs CRSTCHM.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, CRSTCHM.BO has a market cap of 250.6M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while CRSTCHM.BO trades at ₹83.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas CRSTCHM.BO's P/E ratio is 11.26. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, ADLINE.BO is less volatile compared to CRSTCHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CRSTCHM.BO's competition here
ADLINE.BO vs ISHITADR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ISHITADR.BO has a market cap of 206.7M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ISHITADR.BO trades at ₹69.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ISHITADR.BO's P/E ratio is 23.27. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is less volatile compared to ISHITADR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ISHITADR.BO's competition here
ADLINE.BO vs CHEMOPH.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, ADLINE.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check CHEMOPH.BO's competition here
ADLINE.BO vs DECCAN.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, DECCAN.BO has a market cap of 181.2M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while DECCAN.BO trades at ₹7.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas DECCAN.BO's P/E ratio is 7.96. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ADLINE.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check DECCAN.BO's competition here
ADLINE.BO vs ASRL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ASRL.BO has a market cap of 171.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ASRL.BO trades at ₹6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ASRL.BO's P/E ratio is 15.92. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ASRL.BO's competition here
ADLINE.BO vs SUNREST.NS Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SUNREST.NS has a market cap of 156.4M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SUNREST.NS trades at ₹36.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SUNREST.NS's P/E ratio is 7.81. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, ADLINE.BO is less volatile compared to SUNREST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check SUNREST.NS's competition here
ADLINE.BO vs ZENITHHE.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ZENITHHE.BO has a market cap of 149.4M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ZENITHHE.BO trades at ₹2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ZENITHHE.BO's P/E ratio is 34.75. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENITHHE.BO's competition here
ADLINE.BO vs NORRIS.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, NORRIS.BO has a market cap of 127.5M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while NORRIS.BO trades at ₹12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ADLINE.BO's ROE is N/A, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, ADLINE.BO is more volatile compared to NORRIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check NORRIS.BO's competition here
ADLINE.BO vs CHCL.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, ADLINE.BO's ROE is N/A, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, ADLINE.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check CHCL.BO's competition here
ADLINE.BO vs EMMESSA.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, EMMESSA.BO has a market cap of 120M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while EMMESSA.BO trades at ₹24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas EMMESSA.BO's P/E ratio is 37.53. In terms of profitability, ADLINE.BO's ROE is N/A, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check EMMESSA.BO's competition here
ADLINE.BO vs DESHRAK.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, DESHRAK.BO has a market cap of 119.7M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while DESHRAK.BO trades at ₹27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas DESHRAK.BO's P/E ratio is 36.99. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check DESHRAK.BO's competition here
ADLINE.BO vs ZENLABS.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, ZENLABS.BO has a market cap of 119M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while ZENLABS.BO trades at ₹18.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas ZENLABS.BO's P/E ratio is -6.44. In terms of profitability, ADLINE.BO's ROE is N/A, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, ADLINE.BO is less volatile compared to ZENLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check ZENLABS.BO's competition here
ADLINE.BO vs SHAMROIN.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, SHAMROIN.BO has a market cap of 116.1M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while SHAMROIN.BO trades at ₹21.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas SHAMROIN.BO's P/E ratio is -11.56. In terms of profitability, ADLINE.BO's ROE is N/A, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, ADLINE.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check SHAMROIN.BO's competition here
ADLINE.BO vs COLINZ.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, COLINZ.BO has a market cap of 109.5M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while COLINZ.BO trades at ₹43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas COLINZ.BO's P/E ratio is 22.18. In terms of profitability, ADLINE.BO's ROE is N/A, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, ADLINE.BO is less volatile compared to COLINZ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check COLINZ.BO's competition here
ADLINE.BO vs TRINITYLEA.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TRINITYLEA.BO has a market cap of 96.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TRINITYLEA.BO trades at ₹12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TRINITYLEA.BO's P/E ratio is -405.67. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, ADLINE.BO is more volatile compared to TRINITYLEA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check TRINITYLEA.BO's competition here
ADLINE.BO vs PARMAX.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PARMAX.BO has a market cap of 94.4M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PARMAX.BO trades at ₹25.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PARMAX.BO's P/E ratio is -1.86. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PARMAX.BO's ROE of +2.20%. Regarding short-term risk, ADLINE.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check PARMAX.BO's competition here
ADLINE.BO vs BERLDRG.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, BERLDRG.BO has a market cap of 93.3M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while BERLDRG.BO trades at ₹18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas BERLDRG.BO's P/E ratio is 613.33. In terms of profitability, ADLINE.BO's ROE is N/A, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, ADLINE.BO is less volatile compared to BERLDRG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check BERLDRG.BO's competition here
ADLINE.BO vs HINDBIO.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, HINDBIO.BO has a market cap of 76M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while HINDBIO.BO trades at ₹7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas HINDBIO.BO's P/E ratio is 49.40. In terms of profitability, ADLINE.BO's ROE is N/A, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, ADLINE.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check HINDBIO.BO's competition here
ADLINE.BO vs VIVANZA.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, VIVANZA.BO has a market cap of 72M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while VIVANZA.BO trades at ₹1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas VIVANZA.BO's P/E ratio is -45.00. In terms of profitability, ADLINE.BO's ROE is N/A, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, ADLINE.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check VIVANZA.BO's competition here
ADLINE.BO vs GANGAPHARM.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, ADLINE.BO's ROE is N/A, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check GANGAPHARM.BO's competition here
ADLINE.BO vs TIAANC.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TIAANC.BO has a market cap of 68.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TIAANC.BO trades at ₹6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TIAANC.BO's P/E ratio is -67.10. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check TIAANC.BO's competition here
ADLINE.BO vs EVOQ.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, EVOQ.BO has a market cap of 62.7M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while EVOQ.BO trades at ₹2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas EVOQ.BO's P/E ratio is 3.55. In terms of profitability, ADLINE.BO's ROE is N/A, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check EVOQ.BO's competition here
ADLINE.BO vs KOBO.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, KOBO.BO has a market cap of 55.8M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while KOBO.BO trades at ₹2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas KOBO.BO's P/E ratio is -1.10. In terms of profitability, ADLINE.BO's ROE is N/A, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ADLINE.BO is less volatile compared to KOBO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check KOBO.BO's competition here
ADLINE.BO vs DECIPHER.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, DECIPHER.BO has a market cap of 53.8M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while DECIPHER.BO trades at ₹5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas DECIPHER.BO's P/E ratio is -0.67. In terms of profitability, ADLINE.BO's ROE is N/A, compared to DECIPHER.BO's ROE of -0.37%. Regarding short-term risk, ADLINE.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check DECIPHER.BO's competition here
ADLINE.BO vs PATIDAR.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, PATIDAR.BO has a market cap of 46.7M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while PATIDAR.BO trades at ₹8.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas PATIDAR.BO's P/E ratio is -17.69. In terms of profitability, ADLINE.BO's ROE is N/A, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, ADLINE.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check PATIDAR.BO's competition here
ADLINE.BO vs TMTIND-B1.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, TMTIND-B1.BO has a market cap of 36.2M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while TMTIND-B1.BO trades at ₹7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas TMTIND-B1.BO's P/E ratio is 18.74. In terms of profitability, ADLINE.BO's ROE is N/A, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ADLINE.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADLINE.BO.Check TMTIND-B1.BO's competition here
ADLINE.BO vs FABINO.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, FABINO.BO has a market cap of 30.9M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while FABINO.BO trades at ₹14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas FABINO.BO's P/E ratio is -20.14. In terms of profitability, ADLINE.BO's ROE is N/A, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ADLINE.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check FABINO.BO's competition here
ADLINE.BO vs WELCURE.BO Comparison April 2026
ADLINE.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADLINE.BO stands at 73.1M. In comparison, WELCURE.BO has a market cap of 28.1M. Regarding current trading prices, ADLINE.BO is priced at ₹12.50, while WELCURE.BO trades at ₹0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADLINE.BO currently has a P/E ratio of N/A, whereas WELCURE.BO's P/E ratio is 1.09. In terms of profitability, ADLINE.BO's ROE is N/A, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, ADLINE.BO is less volatile compared to WELCURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADLINE.BO.Check WELCURE.BO's competition here